Quantum Genomics (Euronext Growth: FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat resistant hypertension and heart failure, is announcing the appointment of the steering committee for its pivotal Phase III trial of its lead candidate, firibastat, in resistant hypertension.
Phase IIb results published last November demonstrate that firibastat has highly significant anti-hypertensive efficacy in patients at high cardiovascular risk whose hypertension is generally difficult to treat.
In accordance with these results, Quantum Genomics is preparing to launch a Phase III trial studying the effectiveness of firibastat as a treatment for resistant hypertension, thus paving the way for marketing authorisation. The complications of hypertension are particularly severe, and the disease is responsible for 9.4 million deaths worldwide each year.
In order to design and implement this trial, Quantum Genomics has set up a scientific steering committee composed of recognised European and American experts in high blood pressure:
- Keith C. Ferdinand: Cardiologist, Professor of Medicine at the Tulane School of Medicine, and Past President of the National Forum for Heart Disease and Stroke Prevention (New Orleans, USA).
- Georges Bakris: Nephrologist, Professor of Medicine & Director of the University of Chicago Medicine's Comprehensive Hypertension Centre, and Past President of the American Society of Hypertension (Chicago, USA).
- William B. White: Professor of Medicine at the University of Connecticut School of Medicine, Chief of the Calhoun Cardiology Centre's Division of Hypertension and Clinical Pharmacology, and Past President of the American Society of Hypertension (Farmington, USA).
- Jacques Blacher: Cardiologist, Professor at the Paris Descartes University, Head of the Diagnosis and Therapeutics Centre at the Hôtel Dieu University Hospital (AP-HP, Paris), and Past President of the French Society of Hypertension (Paris, France).
The steering committee will work closely with Quantum Genomics' scientific team to define the design of the Phase III trial, in particular its methodology, target population and evaluation criteria, and will be involved in discussions with the EMA (European Medicines Agency) and FDA (Food and Drug Administration). It will also be directly involved in the clinical trial's conduct.
The 2019 Financial Agenda:
2018 Annual Results 28 March 2019, after market close
General Meeting of Shareholders 27 June 2019
2019 Half-Year Results 3 October 2019, after market close
Events Scheduled for the First Half of 2019:
BioMed Event 2019 (Paris) 22 January 2019
American College of Cardiology Congress
(ACC) 2019 (New Orleans) - Quantum Genomics
Symposium From 16 to 18 March 2019
Bio-Europe Spring (Vienna) From 25 to 27 March 2019
SmallCap Event (Paris) From 16 to 17 April 2019
Bio International Convention (Philadelphia) From 2 to 6 June 2019
About Quantum Genomics
Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on its 20-plus years of basic and clinical research at some of the largest French laboratories: the French National Institute of Health and Medical Research (INSERM), the French National Centre for Scientific Research (CNRS), the Collège de France, and Paris-Descartes University. The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with heart failure dies within five years).
Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF).
|Jean-Philippe Milon |
+33 (0)1 85 34 77 70 | firstname.lastname@example.org
|Marc Karako |
CFO - Investor Relations
+33 (0)1 85 34 77 70 | email@example.com
|So Bang (European Investor & Media Contact)|
|Samuel Beaupain |
Media Relations and Scientific Communications
+33 (0)6 88 48 48 02 | firstname.lastname@example.org
|Nathalie Boumendil |
+33 (0)6 85 82 41 95 | email@example.com
|Edison Advisors (U.S. Investor Contact)||LifeSci Public Relations (U.S. Media Contact)|
|Joseph Green |
+1 (646) 653-7030 | firstname.lastname@example.org
|Michael Tattory |
Media Relations and Scientific Communications
+1 (646) 751-4362 | email@example.com
 WHO (World Health Organisation) - A Global Brief on Hypertension: Silent Killer, Global Public Health Crisis (2013).